Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.62 |
| ▸ | MMP2 | P08253 | 1/20 | 0.61 |
| ▸ | MMP7 | P09237 | 1/20 | 0.61 |
| ▸ | MMP9 | P14780 | 1/20 | 0.61 |
| ▸ | MMP12 | P39900 | 1/20 | 0.61 |
| ▸ | MMP13 | P45452 | 1/20 | 0.61 |
| ▸ | MME | P08473 | 3/20 | 0.61 |
| ▸ | CPA1 | P15085 | 1/20 | 0.57 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.57 |
| ▸ | CTSB | P07858 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycylleucylphenylalanine SCHEMBL4281374 | 1.00 | ACE (0.62) | ACEMMP2MMP7MMP9MMP12 | |
| SCHEMBL21192616 | 0.95 | ACE (0.57) | ACEMMP2MMP7MMP9MMP12 | |
| SCHEMBL21192611 | 0.95 | ACE (0.57) | ACEMMP2MMP7MMP9MMP12 | |
| SCHEMBL9551455 | 0.95 | MME (0.64) | ACEMMP2MMP7MMP9MMP12 | |
| SCHEMBL5370772 | 0.95 | MME (0.64) | ACEMMP2MMP7MMP9MMP12 | |
| SCHEMBL9829182 | 0.95 | MME (0.64) | ACEMMP2MMP7MMP9MMP12 | |
| SCHEMBL30396564 | 0.93 | ACE (0.63) | ACEMMP2MMP7MMP9MMP12 | |
| SCHEMBL8983297 | 0.92 | CTSB (0.62) | ACEMMP2MMP7MMP9MMP12 | |
| SCHEMBL8983313 | 0.92 | CTSB (0.62) | ACEMMP2MMP7MMP9MMP12 | |
| SCHEMBL29427560 | 0.92 | MME (0.58) | ACEMMP2MMP7MMP9MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PC, PCK2, CS | ACE 1455/4885MMP2 2846/4885MMP7 2870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.